Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Price Performance

Shares of AGRX stock opened at $1.41 on Monday. The company has a market capitalization of $9.70 million, a price-to-earnings ratio of -0.39 and a beta of 1.56. Agile Therapeutics has a one year low of $0.20 and a one year high of $3.40. The company’s fifty day moving average price is $0.44 and its 200-day moving average price is $0.88.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The firm had revenue of $5.72 million for the quarter.

Hedge Funds Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC grew its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.